Navigation Links
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Date:12/11/2011

p>Dr. Meyer will present this study in an oral presentation on Monday, December 12, at 3:00 p.m. PST at the San Diego Convention Center in Ballroom 20A.

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study [Abstract 269]

The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy.

NHL survival rates have increased dramatically in the last several decades because of such proven and effective targeted therapies as rituximab that aim directly at the key molecular features of the disease. Despite advances in NHL treatment, hematologists continue to be challenged by drug resistance and disease relapses among their patients. Obinutuzumab, also known as GA101, is a new investigational therapy and the first type II bio-engineered monoclonal antibody specifically targeting CD20 (a prominent lymphoma biomarker) to be studied for use in NHL. Early research with GA101 has shown potential anti-lymphoma activity, but no studies have compared the results against current clinical options directly.

To compare the efficacy and safety of GA101 versus rituximab in patients with relapsed NHL, an international Phase II clinical trial was undertaken measuring overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety outcomes among patients on both treatments. A total of 175 patients were randomized to receive four weekly injections of either GA101 or rituximab with response to treatment assessed between 28 and 42 days after the last dose. Those patients who responded to treatment received ongoing doses of GA101 or rituximab every t
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Established and Emerging Biotech Clusters
2. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
3. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications
4. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot
5. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
6. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
7. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
8. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors
9. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
10. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers
11. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 The following is an ... Directors of China Cord Blood Corp (NYSE: CO ) ... committee of the independent directors of China Cord Blood Corp ... offer of $6.40 per share from Golden Meditech Holdings Co ... per share would greatly benefit Golden Med and Mr. Kam, ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
(Date:4/30/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... services provider, today announced that its board of directors ... 29, 2015, from a consortium (the "Consortium") led by ... and chief executive officer of the Company, and Ally ... (the "Transaction") involving the acquisition of all outstanding shares ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health science ... SureClinical’s executive team as Chief Financial Officer. ... with over 25 years in leadership roles ranging from ... Morris joins SureClinical from Marrone Bio Innovations (MBI), a ... MBI from its founding in 2006 until 2011, when ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Julie I. Morris Joins SureClinical as Chief Financial Officer 2
... Fla., Feb. 16, 2012   GeneLink Biosciences, ... company, has completed the sale of the stock ... Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: WELL), ... wellness marketplace.  As previously disclosed, GeneLink and Capsalus ...
... 2012 /PRNewswire-iReach/ -- FirstMark today announced the ... cardiovascular blood test PREvent. These clinical results demonstrate the ... (2-3 years) risk of myocardial infarction and death in ... The clinical study and final data was well received ...
... today the publication of key results relating to its ... high-value G-protein-coupled receptor (GPCR) targets in Science . ... Lipid G Protein-Coupled Receptor," was co-authored by Receptos in ... Raymond Stevens, Ph.D. Drs. Rosen and Stevens are both ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2FirstMark's Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 3Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 4
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... EAC standard by providing ... single platform, DALLAS, Sept. 10 As ePassport ... many seek a method,to deploy border security capabilities in ... ENTU ) and 3M (NYSE: MMM ),announce a ...
... has been awarded $1 million from the US Department ... biomass conversion technologies. The grant is one of six ... develop their advanced biofuels projects. In total, the DOE ... projects for their research into how non-food feedstocks can ...
... of California White Mountain Research Station, U.S. Forest ... Integrated Climate Research in Western Mountains will host ... Tri-Valley Fairgrounds in Bishop. The conference is entitled ... will bring together distinguished researchers from a variety ...
Cached Biology News:Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 2Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 3Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 4Stevens awarded $1M for advanced biofuels research 2
... Collection of Cell Cultures (ECACC) has been ... academia and government institutes for over seven ... designed to introduce candidates to cell culture ... on more specialist areas such as planning ...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
...
Biology Products: